[Answered] The DSM-5 classifies substance-related disorders into _____

This topic contains a solution. Click here to go to the answer

Author Question: The DSM-5 classifies substance-related disorders into ______ major categories. a. two c. four ... (Read 91 times)

Pineapplelove6

Hero Member
Posts: 560

on: Jun 22, 2018

The DSM-5 classifies substance-related disorders into ______ major categories.

a. two c. four
b. three d. five

Question 2

In order to carry out valid research, it may be necessary to keep people unaware of the
treatments they receive.

Indicate whether the statement is true or false

Need homework help now?

Ask unlimited questions for free

Ask a Question

Marked as best answer by a Subject Expert

DylanD1323

Sr. Member
Posts: 314

Reply #1 on: Jun 22, 2018

Answer to Question 1

A

Answer to Question 2

T

Pineapplelove6

Member
Posts: 560

Reply 2 on: Jun 22, 2018

Thanks for the timely response, appreciate it

cici

Member
Posts: 325

Reply 3 on: Yesterday

TYSM

« previous next »

Did you know?

Certain topical medications such as clotrimazole and betamethasone are not approved for use in children younger than 12 years of age. They must be used very cautiously, as directed by a doctor, to treat any child. Children have a much greater response to topical steroid medications.

Did you know?

The people with the highest levels of LDL are Mexican American males and non-Hispanic black females.

Did you know?

Disorders that may affect pharmacodynamics include genetic mutations, malnutrition, thyrotoxicosis, myasthenia gravis, Parkinson's disease, and certain forms of insulin-resistant diabetes mellitus.

Did you know?

As the western states of America were settled, pioneers often had to drink rancid water from ponds and other sources. This often resulted in chronic diarrhea, causing many cases of dehydration and death that could have been avoided if clean water had been available.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.